US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jade Biosciences

10.00

+0.07000.70%

Post-market: 10.000.00000.00%17:49 EDT

Volume:94.32K

Turnover:943.91K

Market Cap:459.95M

PE:-0.53

High:10.20

Open:10.06

Low:9.83

Close:9.93

52wk High:105.00

52wk Low:6.57

Shares:45.99M

Float Shares:32.14M

Volume Ratio:0.49

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-18.7916

EPS(LYR):-9.3958

ROE:--

ROA:--

PB:0.16

PE(LYR):-1.06

Loading ...

Overview Company News Filings

Jade Biosciences Launches Phase 1 Trial of Anti-APRIL Antibody JADE101 for IgA Nephropathy

Jade Biosciences Initiated at Buy by BTIG

Jade Biosciences up 16.5% at $10.65 after JADE201 announcement

Jade Biosciences prices 13.4M shares at $9.14 in private placement

Jade Biosciences Unveils Promising Preclinical Results for JADE201, a Next-Generation Anti-BAFF-R Antibody for Autoimmune Diseases

Jade Biosciences Announces Jade201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-Baff Receptor Monoclonal Antibody in Development for Autoimmune Diseases

THOMSON REUTERS

Jade Biosciences Inc - Jade201 Trial in Rheumatoid Arthritis Expected in 2026

THOMSON REUTERS

Jade Biosciences Announces $135 Million Private Placement to Fund Autoimmune Disease Therapies

Jade Biosciences Announces Departure of Chief Medical Officer, Dr. Hetal Kocinsky, with Dr. Andrew King Leading Scientific and Clinical Programs

Jade Biosciences Inc. Initiates Phase 1 Trial of JADE101, a Promising Anti-APRIL Monoclonal Antibody for IgA Nephropathy Treatment

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of Jade101, a Novel and Potentially Best-in-Class Anti-April Monoclonal Antibody Being Evaluated for the Treatment of Iga Nephropathy

THOMSON REUTERS

Jade Biosciences: Interim, Biomarker-Rich Phase 1 Healthy Volunteer Data Are Expected in First Half of 2026

THOMSON REUTERS

Jade Biosciences Inc. to Participate in Cantor Global Healthcare Conference

Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating

MT Newswires Live

Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate

Jade Biosciences Reports Q2 2025 Net Loss of $32.1M with No Revenue Figures Provided

Jade Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview

Jade Biosciences Inc. Files Initial Beneficial Ownership Statement for CFO Bradford D. Dahms

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer Amid Strategic Growth Initiatives

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/JBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"JBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JBIO\",,,,,undefined,":{"symbol":"JBIO","market":"US","secType":"STK","nameCN":"Jade Biosciences","latestPrice":10,"timestamp":1761336000000,"preClose":9.93,"halted":0,"volume":94316,"hourTrading":{"tag":"盘后","latestPrice":10,"preClose":10,"latestTime":"17:49 EDT","volume":306,"amount":3060.61,"timestamp":1761342567999},"delay":0,"floatShares":32137430,"shares":45994900,"eps":-18.7916,"marketStatus":"Market Closed","change":0.07,"latestTime":"10-24 16:00:00 EDT","open":10.06,"high":10.2,"low":9.83,"amount":943908.9572,"amplitude":0.037261,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-18.7916,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1761552000000},"marketStatusCode":7,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":9.93,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":9.93,"latestTime":"05:02 EDT","volume":54,"amount":486,"timestamp":1761296564300},"postHourTrading":{"tag":"盘后","latestPrice":10,"preClose":10,"latestTime":"17:49 EDT","volume":306,"amount":3060.61,"timestamp":1761342567999},"volumeRatio":0.49243998405732875,"impliedVol":1.1952,"impliedVolPercentile":0.7273},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JBIO\",,,,,undefined,":{"symbol":"JBIO","floatShares":32137430,"roa":"--","roe":"--","lyrEps":-9.3958,"volumeRatio":0.49243998405732875,"shares":45994900,"dividePrice":0,"high":10.2,"amplitude":0.037261,"preClose":9.93,"low":9.83,"week52Low":6.565,"pbRate":"0.16","week52High":105,"institutionHeld":0,"latestPrice":10,"eps":-18.7916,"divideRate":0,"volume":94316,"delay":0,"ttmEps":-18.7916,"open":10.06,"prevYearClose":92.75,"prevWeekClose":9.37,"prevMonthClose":8.63,"prevQuarterClose":8.63,"fiveDayClose":9.37,"twentyDayClose":8.48,"sixtyDayClose":7.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/JBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"JBIO","fiscalQuarterEnding":"2025/06","expectedEps":-0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.86},{"date":"2025-04-29","symbol":"JBIO","amount":2.4,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745933400000,"name":"Jade Biosciences","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-28","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-04-28"},{"market":"US","date":"2025-04-29","symbol":"JBIO","defaultRemindTime":1745933400000,"type":"split","dateTimestamp":1745899200000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2025-04-25","symbol":"JBIO","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745553600000,"reportTimeType":"post","actualEps":-0.09},{"market":"US","date":"2025-03-27","symbol":"JBIO","fiscalQuarterEnding":"2024/12","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"JBIO\",market:\"US\",,,undefined,":[{"executeDate":"2025-04-29","recordDate":"2025-04-25","paymentDate":"2025-04-28","value":2.4,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"JBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.8333,"buy":0.1667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.8333,"analysts":6,"updateTime":1760068800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/JBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"JBIO","date":"2025-10-24","current":-0.532153,"percent":0.095652,"low":-3.822008,"twenty":-3.228464,"median":-2.743259,"eighty":-2.487393,"high":-2.319279,"avg":-2.853152,"sd":0.393227,"marketCap":323983428},"quantilePoints":[{"date":"2025-05-16","current":-2.4743,"twenty":-2.881556,"median":-2.868851,"eighty":-2.514424,"marketCap":232480279},{"date":"2025-05-23","current":-2.511409,"twenty":-2.870857,"median":-2.517932,"eighty":-2.47965,"marketCap":235966978},{"date":"2025-05-30","current":-2.432499,"twenty":-2.695315,"median":-2.507901,"eighty":-2.466944,"marketCap":228552715},{"date":"2025-06-06","current":-2.363881,"twenty":-2.548988,"median":-2.487393,"eighty":-2.464507,"marketCap":222105530},{"date":"2025-06-13","current":-2.381035,"twenty":-2.548988,"median":-2.48419,"eighty":-2.428382,"marketCap":223717326},{"date":"2025-06-20","current":-3.228464,"twenty":-2.618978,"median":-2.48419,"eighty":-2.41603,"marketCap":303340063},{"date":"2025-06-27","current":-3.17357,"twenty":-2.886906,"median":-2.487393,"eighty":-2.426323,"marketCap":298182315},{"date":"2025-07-03","current":-3.822008,"twenty":-3.217485,"median":-2.511409,"eighty":-2.437181,"marketCap":359108215},{"date":"2025-07-11","current":-3.609293,"twenty":-3.553713,"median":-2.554094,"eighty":-2.45809,"marketCap":339121941},{"date":"2025-07-18","current":-3.262773,"twenty":-3.420594,"median":-2.844205,"eighty":-2.467494,"marketCap":306563656},{"date":"2025-07-25","current":-2.857929,"twenty":-3.391775,"median":-2.873866,"eighty":-2.470924,"marketCap":268525263},{"date":"2025-08-01","current":-2.466808,"twenty":-3.382854,"median":-2.844205,"eighty":-2.467494,"marketCap":231776307},{"date":"2025-08-08","current":-2.511409,"twenty":-3.347859,"median":-2.705254,"eighty":-2.467494,"marketCap":235966978},{"date":"2025-08-15","current":-2.350869,"twenty":-3.260028,"median":-2.645214,"eighty":-2.467494,"marketCap":220882962},{"date":"2025-08-22","current":-2.56269,"twenty":-3.244933,"median":-2.581542,"eighty":-2.467494,"marketCap":240785267},{"date":"2025-08-29","current":-2.805764,"twenty":-3.217485,"median":-2.645214,"eighty":-2.470924,"marketCap":263623978},{"date":"2025-09-05","current":-2.70159,"twenty":-3.17357,"median":-2.64603,"eighty":-2.473669,"marketCap":253835959},{"date":"2025-09-12","current":-2.694645,"twenty":-3.152985,"median":-2.64603,"eighty":-2.4743,"marketCap":253183424},{"date":"2025-09-19","current":-2.677282,"twenty":-3.087798,"median":-2.64603,"eighty":-2.473669,"marketCap":251552088},{"date":"2025-09-26","current":-2.798819,"twenty":-3.080936,"median":-2.64603,"eighty":-2.4743,"marketCap":262971443},{"date":"2025-10-03","current":-2.892576,"twenty":-3.080936,"median":-2.67381,"eighty":-2.479351,"marketCap":271780660},{"date":"2025-10-10","current":-3.264131,"twenty":-3.152985,"median":-2.690514,"eighty":-2.480987,"marketCap":306691262},{"date":"2025-10-17","current":-3.397822,"twenty":-3.16343,"median":-2.70159,"eighty":-2.487393,"marketCap":319252553},{"date":"2025-10-24","current":-3.448173,"twenty":-3.228464,"median":-2.743259,"eighty":-2.487393,"marketCap":323983428}],"updateTime":1761519219012},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"JBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2576069632","title":"Jade Biosciences Launches Phase 1 Trial of Anti-APRIL Antibody JADE101 for IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2576069632","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576069632?lang=en_us&edition=fundamental","pubTime":"2025-10-18 04:05","pubTimestamp":1760731511,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc. has announced upcoming presentations of new preclinical safety and translational data for its lead investigational candidate, JADE101, at the American Society of Nephrology  Kidney Week 2025, scheduled for November 5-9 in Houston, Texas. JADE101 is a potentially best-in-class, disease-modifying anti-APRIL monoclonal antibody currently being evaluated in a Phase 1 healthy volunteer clinical trial for the treatment of immunoglobulin A nephropathy . The results from the ongoing Phase 1 study have not yet been presented; interim data are expected in the first half of 2026. The company's poster presentations will focus on JADE101's nonclinical safety profile and the translational framework guiding its clinical development in IgAN.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL3NGWk9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","JBIO","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","BK4585","BK4539","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2574159153","title":"Jade Biosciences Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2574159153","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574159153?lang=en_us&edition=fundamental","pubTime":"2025-10-09 18:20","pubTimestamp":1760005200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 09, 2025 06:20 ET (10:20 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","JBIO","BK4139"],"gpt_icon":0},{"id":"2573522739","title":"Jade Biosciences up 16.5% at $10.65 after JADE201 announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573522739","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573522739?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:56","pubTimestamp":1759838161,"startTime":"0","endTime":"0","summary":"07:50 EDT Jade Biosciences (JBIO) up 16.5% at $10.65 after JADE201 announcement Published first on TheFly – the ultimate source for real-time, mark...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jade-biosciences-up-16-5-at-10-65-after-jade201-announcement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jade-biosciences-up-16-5-at-10-65-after-jade201-announcement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2573954608","title":"Jade Biosciences prices 13.4M shares at $9.14 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2573954608","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573954608?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:15","pubTimestamp":1759835733,"startTime":"0","endTime":"0","summary":"Jade Biosciences (JBIO) entered into a securities purchase agreement for a private investment in public equity financing that is expected to result...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jade-biosciences-prices-13-4m-shares-at-9-14-in-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jade-biosciences-prices-13-4m-shares-at-9-14-in-private-placement-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JBIO","BK4539","BK4139"],"gpt_icon":0},{"id":"2573951032","title":"Jade Biosciences Unveils Promising Preclinical Results for JADE201, a Next-Generation Anti-BAFF-R Antibody for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2573951032","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573951032?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:05","pubTimestamp":1759835113,"startTime":"0","endTime":"0","summary":"Jade Biosciences Unveils Promising Preclinical Results for JADE201, a Next-Generation Anti-BAFF-R Antibody for Autoimmune Diseases. Jade Biosciences Inc., a clinical-stage biotechnology company specializing in autoimmune disease therapies, has unveiled JADE201, an investigational half-life extended, afucosylated monoclonal antibody targeting the B-cell activating factor receptor . JADE201 is designed to improve upon existing B-cell depleting therapies by offering a dual mechanism of action and extended dosing intervals. The company announced plans to initiate a first-in-human study of JADE201 in patients with rheumatoid arthritis in the first half of 2026. The upcoming randomized, placebo-controlled trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics, with detailed biomarker analysis. These results have not yet been presented; Jade Biosciences will discuss the JADE201 profile in a conference call and webcast scheduled for today.Disclaimer: This news brief w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL19FPg9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","BK4585","BK4112","IE00BGHQF748.EUR","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","JBIO","LU2210149790.SGD","BK4139","BK4539"],"gpt_icon":0},{"id":"2573595171","title":"Jade Biosciences Announces Jade201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-Baff Receptor Monoclonal Antibody in Development for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2573595171","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573595171?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:05","pubTimestamp":1759835100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA1GFH4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2573039951","title":"Jade Biosciences Inc - Jade201 Trial in Rheumatoid Arthritis Expected in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2573039951","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573039951?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:05","pubTimestamp":1759835100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nTUA1GFH4J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2573951428","title":"Jade Biosciences Announces $135 Million Private Placement to Fund Autoimmune Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2573951428","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573951428?lang=en_us&edition=fundamental","pubTime":"2025-10-07 19:00","pubTimestamp":1759834823,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc. , a clinical-stage biotechnology company focused on therapies for autoimmune diseases, has announced a private placement expected to raise approximately $135 million in gross proceeds. The financing saw participation from both new and existing investors, including Janus Henderson Investors, RA Capital Management, Marshall Wace, and others. Under the terms of the agreement, Jade Biosciences is selling 13,368,164 shares of common stock at $9.14 per share and pre-funded warrants to purchase 1,402,092 shares at $9.1399 per warrant. The pre-funded warrants have an exercise price of $0.0001 per share and can be exercised at any time, subject to certain ownership limitations. Following the transaction, Jade will have about 67.4 million shares and equivalents outstanding. Jefferies, TD Cowen, Stifel, and Wedbush & Co. are acting as placement agents for the transaction. The company plans to use the net proceeds to support research and development, general corporate purpose","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDLbPTywX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","BK4585","BK4127","IE00BGHQF748.EUR","NDAQ","LU0054578231.USD","IE00B3QW5Z07.USD","SF","BK4139","BK4588","BK4112","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","BK4135","IE00BKPKM429.USD","JBIO","JHG","BK4539"],"gpt_icon":0},{"id":"2566169977","title":"Jade Biosciences Announces Departure of Chief Medical Officer, Dr. Hetal Kocinsky, with Dr. Andrew King Leading Scientific and Clinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2566169977","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566169977?lang=en_us&edition=fundamental","pubTime":"2025-09-09 19:14","pubTimestamp":1757416447,"startTime":"0","endTime":"0","summary":"Jade Biosciences Announces Departure of Chief Medical Officer, Dr. Hetal Kocinsky, with Dr. Andrew King Leading Scientific and Clinical Programs. Jade Biosciences Inc. has announced that effective September 9, 2025, Dr. Hetal Kocinsky has departed from her role as Chief Medical Officer. The company's scientific and clinical programs will continue to be led by Dr. Andrew King, Ph.D, who serves as Chief Scientific Officer and Head of Research & Development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 09, 2025","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250909:nNDL118Pll:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4139","BK4539"],"gpt_icon":0},{"id":"2564589809","title":"Jade Biosciences Inc. Initiates Phase 1 Trial of JADE101, a Promising Anti-APRIL Monoclonal Antibody for IgA Nephropathy Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564589809","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564589809?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:00","pubTimestamp":1756810835,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc. Initiates Phase 1 Trial of JADE101, a Promising Anti-APRIL Monoclonal Antibody for IgA Nephropathy Treatment. Jade Biosciences, Inc. has announced the dosing of the first cohort in a Phase 1 healthy volunteer trial of its investigational monoclonal antibody, JADE101. This clinical-stage biotechnology company is focusing on developing therapies for autoimmune diseases, with JADE101 being evaluated for its potential in treating immunoglobulin A nephropathy . The Phase 1 trial is a randomized, double-blind, placebo-controlled study, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the monoclonal antibody. Interim data from this trial is expected in the first half of 2026. This data is anticipated to provide insights into dose and dosing interval selection for future patient studies, leveraging biomarker responses associated with clinical activity in IgAN patients.Disclaimer: This news brief was created by Public Technologies  using genera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL2K95Jz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","BK4588","LU2210150020.SGD","LU2210149790.SGD","JBIO","NDAQ","IE00B64PRP62.GBP","BK4539"],"gpt_icon":0},{"id":"2564756806","title":"Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of Jade101, a Novel and Potentially Best-in-Class Anti-April Monoclonal Antibody Being Evaluated for the Treatment of Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2564756806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564756806?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:00","pubTimestamp":1756810800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA21NKRR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","JBIO","BK4139"],"gpt_icon":0},{"id":"2564094778","title":"Jade Biosciences: Interim, Biomarker-Rich Phase 1 Healthy Volunteer Data Are Expected in First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2564094778","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564094778?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:00","pubTimestamp":1756810800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nTUA21NKRR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","JBIO"],"gpt_icon":0},{"id":"2562245879","title":"Jade Biosciences Inc. to Participate in Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2562245879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562245879?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:00","pubTimestamp":1756119610,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc., a biotechnology company specializing in autoimmune disease therapies, is set to participate in the Cantor Global Healthcare Conference on September 3-5, 2025. The company will present a fireside chat on Tuesday, September 3 at 3:20 p.m. ET. A live webcast of this presentation will be available on the Jade Biosciences website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on August 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL98rVdF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4585","BK4112","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","JBIO","IE00BGHQF748.EUR","BK4539"],"gpt_icon":0},{"id":"2559959764","title":"Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2559959764","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559959764?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:04","pubTimestamp":1755169460,"startTime":"0","endTime":"0","summary":"Jade Biosciences (JBIO) has an average rating of buy and mean price target of $16.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JBIO"],"gpt_icon":0},{"id":"2559897389","title":"Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559897389","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559897389?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:15","pubTimestamp":1755116153,"startTime":"0","endTime":"0","summary":"Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47106506/jade-biosciences-q2-eps-0-86-misses-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2559890449","title":"Jade Biosciences Reports Q2 2025 Net Loss of $32.1M with No Revenue Figures Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2559890449","media":"Reuters","labels":["event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559890449?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:09","pubTimestamp":1755115791,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on August 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL6bczXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","JBIO"],"gpt_icon":0},{"id":"2557522326","title":"Jade Biosciences Inc  expected to post a loss of 43 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557522326","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557522326?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:46","pubTimestamp":1754657181,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc  expected to post a loss of43cents a share - Earnings Preview Jade Biosciences Inc JBIO.OQ JBIO.O is expected to  show no change in quarterly revenue when it reports  results on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U01ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2551013990","title":"Jade Biosciences Inc. Files Initial Beneficial Ownership Statement for CFO Bradford D. Dahms","url":"https://stock-news.laohu8.com/highlight/detail?id=2551013990","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551013990?lang=en_us&edition=fundamental","pubTime":"2025-07-15 07:11","pubTimestamp":1752534685,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc. has filed an initial statement of beneficial ownership, identifying Bradford D. Dahms as the beneficial owner in his role as Chief Financial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL1dBXnp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2549185549","title":"Jade Biosciences to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2549185549","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549185549?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and VANCOUVER, British Columbia, July  08, 2025  (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111586/0/en/Jade-Biosciences-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","JBIO","BK4139"],"gpt_icon":0},{"id":"2548003512","title":"Jade Biosciences Appoints Brad Dahms as Chief Financial Officer Amid Strategic Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2548003512","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548003512?lang=en_us&edition=fundamental","pubTime":"2025-07-01 19:00","pubTimestamp":1751367617,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc., a biotechnology company focused on therapies for autoimmune diseases, has appointed Brad Dahms as its new Chief Financial Officer. Dahms brings extensive experience in corporate strategy, business development, and capital markets, having previously held CFO positions at IDRx and Theseus Pharmaceuticals. His appointment follows Jade Biosciences' recent Nasdaq listing and private financing, as the company advances its lead candidate JADE101 into clinical trials for IgA nephropathy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on July 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL6fy36S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4539","LU2210149790.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD","JBIO","IE00BGHQF748.EUR","LU2210150020.SGD","BK4139","IE00B64PRP62.GBP","BK4112","BK4588","NDAQ"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}